Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Allogene Therapeutics, Inc.

Market Cap 670M 577M 531M 499M 937M 63.35B 948M 6.26B 2.44B 31B 2.51B 2.46B 107B P/E Ratio 2026 *
-2.72x
P/E Ratio 2027 * -2.55x
Enterprise Value 484M 417M 384M 361M 677M 45.78B 685M 4.53B 1.77B 22.4B 1.82B 1.78B 77.62B EV / Sales 2026 *
80,653x
EV / Sales 2027 * 43.8x
Free-Float
83.55%
Yield 2026 *
-
Yield 2027 * -
1 day-2.06%
1 week+2.70%
Current month-12.44%
1 month-5.00%
3 months-20.83%
6 months+29.25%
Current year+38.69%
1 week 1.75
Extreme 1.75
2.1
1 month 1.75
Extreme 1.75
2.32
Current year 1.31
Extreme 1.31
4.46
1 year 0.98
Extreme 0.9842
4.46
3 years 0.86
Extreme 0.8621
6.05
5 years 0.86
Extreme 0.8621
27.86
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 66 01/06/2018
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 66 01/06/2018
Director/Board Member 49 01/11/2017
Date Insider Type Main position Quantity % Market Cap.
04-21Sell

Controller/Auditor

9,586 0.0039%
03-31Sell

Chief Technology Officer

2,867 0.0013%
03-16Sell

Founder

47,763 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%+2.70%+41.79%-61.77% 670M
-0.71%-0.97%+50.38%+109.48% 54.92B
-1.22%+2.25%+43.78%+38.45% 44.31B
-1.43%+4.68%-16.02%-20.80% 22.96B
-1.99%+1.43%-3.25%+377.36% 21.12B
-2.91%-1.18%+7.21%-36.53% 16.31B
-2.38%-3.41%+5.06%-40.72% 15.19B
-1.70%+0.70%+25.27%+172.77% 13.32B
+1.48%+11.36%+22.59% - 12.48B
+4.10%+7.02%+104.41%+226.33% 11.21B
Average -0.88%+2.89%+28.12%+84.95% 21.25B
Weighted average by Cap. -0.99%+2.02%+29.56%+93.96%

Financials

2026 *2027 *
Net sales 6K 5.17K 4.76K 4.47K 8.39K 568K 8.49K 56.13K 21.89K 278K 22.52K 22.04K 962K 12.97M 11.18M 10.28M 9.67M 18.15M 1.23B 18.36M 121M 47.34M 601M 48.68M 47.65M 2.08B
Net income -197M -169M -156M -146M -275M -18.6B -278M -1.84B -717M -9.1B -738M -722M -31.53B -227M -196M -180M -169M -318M -21.49B -321M -2.13B -829M -10.51B -852M -834M -36.43B
Net Debt -186M -160M -147M -138M -260M -17.57B -263M -1.74B -678M -8.6B -697M -682M -29.78B -101M -86.84M -79.9M -75.11M -141M -9.54B -143M -943M -368M -4.67B -378M -370M -16.17B
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
16/06/26 1.910 $ -1.55% 5,041,616
15/06/26 1.940 $ +2.11% 5,800,150
12/06/26 1.900 $ +1.06% 8,642,431
11/06/26 1.880 $ +5.62% 6,102,343
10/06/26 1.780 $ -2.20% 7,943,853
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.940USD
Average target price
8.485USD
Spread / Average Target
+337.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!